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anti-angiogenic therapies are currently evaluated in advanced
hepatocellular carcinomas. Few biological data are currently
available from patients that may help understanding mecha-
nisms of acquired resistance to these drugs. Herein, we report
translational data from a post-treatment surgical specimen in a
patient who experienced acquired resistance to sunitinib.
Methods: Clinical, radiological, and pathological data were col-
lected before treatment, under treatment, and at the time of
tumor progression. In addition, a biomolecular analysis was per-
formed at the time of progression.
Results: In this patient with non-alcoholic steatohepatitis, initial
response to sunitinib was followed by tumor progression within
6 months of treatment, requesting salvage surgical resection. Sur-
prisingly, pathological examination on post-treatment specimens
revealed the presence of two juxtaposed tissue components con-
taining either sarcomatoid-likemesenchymal cells or well- tomod-
erately-differentiated hepatocellular carcinoma cells. Cancer cells
retain a high a-fetoprotein expression in both components. How-
ever, while cells from carcinoma expressed E-cadherin but no
vimentin, cancer cells from the mesenchymal component highly
expressed vimentin and lost E-cadherin protein expression asmea-
sured by immunostaining. HMGA2 and Ki67 mRNA were also
expressed at higher levels inmesenchymal than in carcinoma cells.
Conclusion: This case report suggests the occurrence of an epi-
thelial-to-mesenchymal transition in discrete areas of hepatocel-
lular carcinomas developing resistance to sunitinib.
 2011 Published by Elsevier B.V. on behalf of the European
Association for the Study of the Liver.Journal of Hepatology 20
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epithelial-to-mesenchymal transition.Hepatocellular carcinoma (HCC) ranks worldwide as the 5th
cause of cancer and the 3rd reason of cancer mortality. While
chemotherapy demonstrated limited effects in HCC, VEGF (Vas-
cular Endothelial Growth Factor), and its corresponding VEGF
receptors (VEGFR) as well as platelet derived growth factor recep-
tors (PDGFR) have been shown to be attractive molecules for sev-
eral targeted therapies. Several drugs directed toward VEGF
(bevacizumab) and VEGFR/PDGFR (sorafenib and sunitinib) dem-
onstrated activity in a number of malignancies. In HCC, the
SHARP (Sorafenib HCC Assessment Randomized Protocol) study
was the ﬁrst to show a 40% improvement of overall survival in
patients with advanced HCC treated with sorafenib compared
to placebo [1], leading to the approval of sorafenib in advanced
HCC and paving the way for further development of VEGFR/
PDGFR inhibitors in this disease. Sunitinib is another multitarget
tyrosine kinase inhibitor showing promising activity in phase II
studies with sustained progression-free survival [2] and leading
to the launch of a large multicenter phase III trial comparing
sorafenib to sunitinib. Despite the activity of multitarget tyrosine
kinase inhibitors, most patients who initially beneﬁt from treat-
ment will ﬁnally experience secondary resistance to these
targeted therapies. A better understanding of mechanisms associ-
ated with resistance may lead to the discovery of novel therapy
strategies and/or optimal combinations. The following report
illustrates the case of a patient who developed progression under
sunitinib and for whom pathological examination provided some
clues into understanding the mechanisms of resistance to
sunitinib.Case report
A 71-year-old man was admitted in the hospital for abnormali-
ties of liver tests. Medical history revealed obesity (body mass
index = 37), with no history of alcohol abuse, grade 1 arterial
hypertension and myasthenia. Morphological aspect of liver
tumor mass observed in computerized tomography scan and
elevation of the a-fetoprotein (a-FP) were typical of HCC. This
diagnosis was further conﬁrmed by a liver biopsy, showing a11 vol. 54 j 1073–1078
Fig. 1. HCC tomodensitometric aspect at baseline (A), under anti-angiogenic treatment (B), and at progression (C). Lower images are schemes representing the tumor
in green and necrosis in gray. Exposure to sunitinib was associated with occurrence of central tumor necrosis and regrowth from peripheral part of the tumor at the time of
progression.
Case Reportwell-differentiated HCC associated with liver ﬁbrosis (F3). Viral
HBV and HBC serologies were negative and the diagnosis of
HCC developed from non-alcoholic steatohepatitis was estab-
lished. After a multidisciplinary evaluation with surgeons,
radiologists, and oncologists, neither surgical resection nor
chemoembolization (portal vein obstruction) were easily possible
and, since sorafenib was not approved at that time, with the
patient’s consent, he entered a phase II study evaluating the anti-
tumor activity of sunitinib.
The patient received sunitinib for four consecutive weeks
every 6 weeks, initially at the dose of 50 mg/day for 4 weeks then
subsequently at 37.5 mg daily dosing due to skin toxicity and
asthenia. The ﬁrst tumor evaluation performed after 4 weeks of
therapy showed tumor stabilization according to RECIST criteria.
As illustrated in Fig. 1A and B, exposure to sunitinib was associ-
ated with an occurrence of central tumor hypodensity on CT-scan
as compared to baseline. Hypodensity has been frequently
described under targeted therapy and was thought to reﬂect
the occurrence of tumor necrosis. Criteria including both changes
in tumor size and measuring tumor hypodensity in gastrointesti-
nal stromal tumors were recently proposed by Choi and cowork-
ers [3] and were found to be applicable in HCC [2]. In our patient
both clinical and radiological assessments encouraged us to
maintain therapy for up to 24 weeks.
At week 25, this patient was referred to hospital for abdomi-
nal pain, lombalgias, and anorexia. At registration, the a-FP level1074 Journal of Hepatology 2011had increased signiﬁcantly and the CT-scan showed an increase
in tumor size corresponding to a disease progression according
to RECIST criteria (Fig. 1C). Furthermore, this increased tumor
size was associated with changes in tumor density at the periph-
ery of the tumor with an increased thickness of a well-vascular-
ized tumor rim. Those radiological features were consistent with
the occurrence of an acquired resistance to sunitinib. In the
absence of other possible therapy and the tumor remaining
restricted to the liver with no distant metastasis, it was decided
to propose a salvage surgical resection and the patient underwent
a right hepatectomy.
Macroscopic pathological examination of the liver resection
showed a 28 cm-long heterogeneous tumor with ﬂeshy beige
areas associated with cholestatic, necrotic, and hemorrhagic
areas (Fig. 2A), associated with liver ﬁbrosis (F3). Microscopic
analysis led to the identiﬁcation of two different tumor compo-
nents. The ﬁrst component was mainly restricted to the inner
part of the tumor and was made by well- to moderately-differen-
tiated HCC (Fig. 2B). In this patient, pathological and immunohis-
tochemical aspects of this well-differentiated component
obtained after surgical resection were similar to those obtained
on the liver biopsy at diagnosis. The patient also displayed a sec-
ond tumor component made by non-cohesive, fusiform cells,
with marked cellular mesenchymal dedifferentiation, consistent
with a sarcomatous aspect (Fig. 2C). This second component
was located on surrounding areas of the tumor, invading adjacentvol. 54 j 1073–1078
Fig. 2. Pathological analysis at the time of progression under sunitinib. Macroscopic examination (A) showed heterogeneous tumor with ﬂeshy beige areas associated
with cholestatic, necrotic, and hemorrhagic areas. Microscopic examination identiﬁed one component made by well- to moderately-differentiated HCC (B) and one
component made by sarcomatoïd-like cells (C).
JOURNAL OF HEPATOLOGYnon-tumor tissues. This analysis was completed by immunohis-
tochemistry. Cells in both components expressed strong a-FP
immunostaining; but while the well-differentiated component
highly expressed E-cadherin and did not express vimentin, the
mesenchymal section displayed a strong vimentin immunostain-
ing and lost E-cadherin expression (Fig. 3). By immunohisto-
chemistry, N-cadherin expression was found poorly expressed
in both component of the tumor without conspicuous differences.
In order to provide additional data consistent with mesenchy-
mal dedifferentiation, we further analyzed this tumor from avail-
able remaining frozen tissues by qRT-PCR comparing mRNA
expression of a selected panel of genes involved in cell prolifera-
tion and differentiation with that of the adjacent liver (Fig. 3).
Comparing tumor tissues and adjacent non-tumor hepatic tis-
sues, we found no difference for E-cadherin and N-cadherin
mRNA expressions. We previously showed that in cancer cell
acquiring a mesenchymal phenotype the gene expression was
down-regulated for S100A4, also known as the ﬁbroblast-speciﬁc
protein 1, Claudin 4 a protein involved in tight junctions of epi-
thelial cells, and mucin MUC1, a gene encoding for a membrane
bound glycosylated phosphoprotein that anchored to the apical
surface of epithelia, [4]. In this study, mRNA expression levels
of Claudin 4, S100A4, and MUC1 wereP4-fold decreased whereas
HMGA2 (High-Mobility Group AT-hook 2) and Ki67 mRNA levels
were, respectively, 5- and 2.5-fold increased in the tumor as com-
pared to non-tumor liver. Comparing the mesenchymal and the
epithelial components, we observed no difference in mRNA
expressions for E-cadherin, N-cadherin, S100A4, Claudin 4, and
MUC1 but slight differences in KI67 and HMGA2mRNA expression
levels. In this report, qRT-PCR data strongly suggested that under
treatment with sunitinib, cancer cells repressed the expression of
genes involved in epithelial differentiation, which along with theJournal of Hepatology 2011strong vimentin and the loss of E-cadherin immunostaining, sug-
gested that cells might have initiated EMT in some area of the
tumor.Discussion
Sarcomatoid differentiation is a growth pattern characterized by
spindle-shaped histology i.e. ﬁbroblast-like appearance that can
be observed across all subtypes of renal cell as well hepatocellu-
lar carcinoma, typically yielding a poor prognosis. Interestingly,
ﬁbroblast-like cancer cells with sarcomatoid features may
express various levels of epithelial and mesenchymal markers
including cytokeratin, vimentin, and serum response factor in
HCC – a phenotype consistent with the deﬁnition of EMT [5,6].
EMT is a physiological process involved during normal embryonic
development. Typically, epithelial cells are (apico-basally) polar-
ized closely joining each other through tight junctions, whereas
mesenchymal cells are less structured, having no intercellular
junctions and greater motility. EMT was recently described in
tumoral tissues and this phenomenon is thought to be a major
factor in tumor growth, angiogenesis, and metastasis [7]. During
EMT, carcinoma cells undergo a loss of epithelial markers and
acquire mesenchymal properties. Vimentin is the mesenchymal
marker most commonly associated with EMT. Vimentin expres-
sion is associated with a gain in cell motility and invasiveness
[8]. High expression of vimentin is usually associated with
down-regulation of E-cadherin, a protein involved in tight junc-
tions, and up-regulation of N-cadherin, a protein being expressed
essentially during cell migration. In the last years, several in vitro
studies have shown that tumor cells that acquire an EMT-pheno-
type may become resistant to several anticancer agents such asvol. 54 j 1073–1078 1075
Fig. 3. Proteins (immunohistochemistry) and mRNA (qRT-PCR) expressions of biomarkers in the carcinoma and the mesenchymal components of a hepatocellular
carcinoma at the time of sunitinib progression. (A) Cells in both components expressed strong a-FP immunostainings. The well-differentiated carcinoma component
expressed E-cadherin and did not express vimentin, while the mesenchymal section displayed no E-cadherin expression and a strong vimentin immunostaining. (B) mRNA
of S100A4, Claudin 4, and MUC1 were down regulated in both tumor components compared to adjacent liver, whereas Ki67 and HMGA2 were up-regulated. mRNA of N-
cadherin remained unchanged.
Case Reportconventional cytotoxics (oxaliplatin [9] and paclitaxel [10]) as
well as targeted therapies (protein kinase C modulators [4] and
epithelial growth factor receptor 1 inhibitors [11]). To our knowl-
edge, the acquisition of an EMT phenotype during a process lead-
ing to acquire resistance to targeted therapy has never been
observed in tumor biopsy from a hepatocellular patient in the
context of treatment with a multikinase inhibitor such as suniti-
nib. The presence of mesenchymal cells coexisting with well-dif-
ferentiated carcinoma cells at diagnosis has been previously
described in HCC but remains an uncommon feature. In our case
report, the high a-FP immunostaining in both tumor components
suggests that cancer cells in the mesenchymal component still
express some characteristics typically observed in hepatocytes
and, therefore, may derive from carcinoma cells that were pres-
ent at diagnosis prior to sunitinib treatment.
As expected during EMT, mesenchymal cancer cells in this
tumor were poorly differentiated and presented high prolifera-
tive capacity, as demonstrated by the high number of cells
expressing Ki67. In this tumor, the strong expression of vimentin
and the loss of markers of cellular adhesion such as E-cadherin
and Claudin 4 in mesenchymal cancer cells are other common
features typically observed in cells undergoing EMT. Therefore,
it is likely that sunitinib treatment either (1) selected an already
preexisting subpopulation of mesenchymal cells that existed in1076 Journal of Hepatology 2011the tumor prior treatment and progressively became predomi-
nant or (2) induced cell signaling changes that progressively
stimulated the transcriptional EMT machinery toward a mesen-
chymal differentiation in an increasing number of cancer cells
over time.
In this case-report, we detected major transcriptional changes
between tumor and non-tumor tissues, mainly oriented with a
reduced expression of genes involved in epithelial differentiation.
However, we were surprised to observe that most transcriptional
changes observed in mesenchymal cells were also observed in
well-differentiated carcinoma cells. This suggested that cancer
cells becoming resistant to sunitinib, although still bearing a dif-
ferentiated carcinoma phenotype, already started activating tran-
scription factors of EMT. Upon investigating factors known to
activate transcription, we found that tumor exposed to sunitinib
over-expressed HMGA2. The high-mobility group A proteins
(HMGA1 and HMGA2, formerly HMGI/Y and HMGI/C, respec-
tively) are non-histone chromatin architectural proteins acting
on the promoter/enhancer regions of several genes and promot-
ing the recruitment of transcription factors participating in cellu-
lar growth, differentiation, and EMT. The over-expression of
HMGA proteins correlates with the occurrence of metastasis
and poor prognosis in several human cancers. HMGA2 is a
nuclear factor that binds AT-rich DNA sequences, contributingvol. 54 j 1073–1078
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to transcriptional regulation in tumors that has recently emerged
as a transcriptional organizer of key signaling molecules such as
SNAIL involved in EMT [12], making HMGA2 a major factor in
tumor growth and invasion [13]. Data presented in this report
supports the important role of HMGA2 in EMT occurring in HCC
during treatment with sunitinib.
Interestingly, despite a lower E-cadherin protein expression in
the mesenchymal components, we found no difference in the
E-cadherinmRNA levels between the epithelial and mesenchymal
components. This feature may be either due to contaminations of
mesenchymal crunch tissues by well-differentiated carcinoma
cells and non-tumor hepatocytes during mRNA extraction or
maybe related to higher E-cadherinprotein degradation inmesen-
chymal cells. Another explanationwouldbe that cancer cellsmight
not have completely silenced the expression of all EMT genes. This
later feature has been observed in patients with renal cell carcino-
mas resistant to sunitinibwhere cytokeratin and vimentin expres-
sion may sometimes coexist together within cancer cells [14].
Furthermore, as observed in renal carcinoma, EMT may be fully
reversible, suggesting some plasticity in the transcriptional activa-
tion of epithelial andmesenchymal genotypes that could allow the
presence of both phenotypes in some tumors [14].
Different mechanisms of sunitinib resistance have been
reported such as the expression of additional proangiogenic
growth factors, the recruitment of bone marrow-derived cells,
increased pericyte coverage, as well as angiogenesis-independent
growth patterns. Sunitinib appears as a paradigm drug capable of
inducing tumor hypoxia and necrosis, as illustrated in our case
report by the occurrence of a large area of tumor hypodensity
on CT-scan suggesting either a reduced vascularisation and/or
necrosis. Tumor reactions induced by sunitinib in hypoxic and
necrotic condition may drive mechanisms of acquired resistance.
Tumor cells may adapt to a hypoxic environment by activating
speciﬁc pathways associated with hypermetabolism, glycolysis
and resistance to acidosis-induced toxicity as well as secondary
developed neoangiogenesis. Suggested mechanisms included a
selection of cells that can better tolerate hypoxia and, in the set-
ting of intrinsic resistance to VEGF inhibition, the recruitment of
CD11b and Gr1-positive bone marrow-derived proangiogenic
cells [15]. Hypoxia genes that are expressed within solid tumors
may result in discrete changes within different areas of tumors,
probably contributing to tumor heterogeneity. The link between
hypoxia and EMT has been strengthened by the observed activa-
tion of EMT transcription factor expression by HIF-1. Another
hypoxia-related gene, lysyl oxidase, was found to interact directly
with SNAIL, another transcription factor of EMT [16]. Another
speciﬁc feature of the tumor microenvironment is the stromal
reaction through which epithelial–mesenchymal interactions
activate or regulate several pathways involving integrins, cyto-
kines, chemokines, and growth factors that are critical for tumor
growth and metastasis. Sunitinib being ﬁrst registered in kidney
cancer, resistance to sunitinib has been ﬁrst observed and
described in renal cell carcinoma. Hammers et al. have described
the de novo onset of an EMT-like phenotype in a patient with
conventional clear renal cell carcinoma on sunitinib treatment.
In this report, authors have observed an induction of HIF-1a
staining in the skin metastasis as compared with the nephrec-
tomy sample that resolved in the xenografts [14]. The reverted
histological phenotype observed in the renal cancer xenografts
suggested that the escape mechanisms against anti-VEGFR ther-
apies might be transient. Proposed resistance mechanismsJournal of Hepatology 2011include an increase in alternative proangiogenic factors such as
interleukin-8 (IL-8) and basic ﬁbroblast growth factor as seen in
the setting of anti-VEGFR2 antibody therapy. The empty base-
ment membrane sheaths and pericyte changes [17,18] may pro-
vide the scaffold for tumor angiogenesis in the resistant setting.
Bhatt et al. showed that CXCL9 treatment delays resistance to
sunitinib in 786-O- and A498-derived tumors suggesting that
angiostatic pathways are suppressed as a result of VEGFR inhibi-
tors and set the stage for the subsequent development of resis-
tance to therapy [19]. CXCR3, the receptor for CXCL9, is
expressed on both tumor cells and endothelium. CXCR3 signaling
in other tumor types has pro-invasive properties. The fact that
these angiostatic molecules are expressed by tumor cells in
untreated mice and even over-expressed in some tumors that
have developed resistance to sunitinib indicates that their pres-
ence is not an absolute deterrent to tumor growth and vascular-
ization. This observation also indicated that the early phases of
tissue remodeling induced by VEGFR blockade are affected by
the presence of CXCL9 and that the disappearance of this chemo-
kine from the tissue facilitates the re-establishment of the tumor
micro-circulation and the development of resistance to VEGFR
antagonists. Huang et al. showed that the development of suniti-
nib resistance was accompanied by an increased expression of
tumor-derived IL-8, another proangiogenic chemokine that may
functionally compensate for the inhibition of VEGF/VEGFR-med-
iated angiogenesis [20]. Shojaei et al. also investigated modes of
resistance to sunitinib in renal cell carcinoma showing that the
hepatocyte growth factor and its related receptor c-MET pathway
were involved in the development of resistance to anti-angio-
genic VEGFR therapy [21]. Elucidation of the mechanisms under-
lying the acquired resistance to VEGFR blockade may contribute
to the development of novel therapeutic approaches that could
enhance the efﬁcacy of VEGFR inhibitors in clinical trials.
Altogether, our data suggest that under protracted exposure
to sunitinib, HCC may develop resistance that is associated with
transcriptional, immunohistochemical, and morphological
changes that are consistent with the activation of EMT.
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